Correction
In the article by Varma et al, “Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial,” which published online May 27, 2018, and appeared in the June 5, 2018 issue of the journal (J Am Heart Assoc. 2018;7:e009592 DOI: 10.1161/JAHA.118.009592), on page 12, in the Disclosures section, the acknowledgement of individual research grants and consulting fees unrelated to the study had not been stated. These have now been added.
Individual disclosures are: Varma: consulting fees from Biotronik, Abbott, Medtronic; Sogaard: Research grants from BIOTRONIK and GE Health Care; Consultant AstraZenaca and BIOTRONIK; Bax: department received unrestricted research grants from Biotronik, Medtronic, Boston Scientific, Ge Healthcare, and Edwards Lifescience; Abraham: consulting fees from Biotronik; Borer: consulting fees from Amgen, Servier, Pfizer, AstraZeneca, GTilead, General Electric, GSK, Novartis, and ARMGO; Dickstein: none; Singh: consulting fees from Abbott, Boston Sci, Biotronik, MEDTRONIC, Liva Nova, Impulse dynamics; Gras: consulting fees from Medtronic, Biotronik, Abbott (Saint jude medical), Boston; Holzmeister: consulting fees from Biotronik; Brugada: consulting fees from Biotronik; Ruschitzka: research grants from St Jude Medical, Novartis; personal fees for lectures from St Jude Medical, Servier, Zoll, Novartis, Bayer, and Abbott; personal fees for advisory board or steering committee clinical trial meetings from AstraZeneca, Sanofi, Cardiorentis, Amgen, BMS, Pfizer, Fresenius, Vifor, and Rochen.
The authors regret the error.
The online version of the article has been updated and is available at http://jaha.ahajournals.org/content/7/11/e009592.
J Am Heart Assoc. 2018;7:e004259 DOI: 10.1161/JAHA.117.004259.